Morningstar maintains fair value estimates on Aussie health firms despite Trump's 200% tariffs plan

** Analysts at Morningstar maintain fair value estimates on Australian health companies, anticipating a change in U.S. President Donald Trump's position on pharmaceutical tariffs

** Trump said on Tuesday he plans to announce tariffs on imported pharmaceuticals to the U.S. which could reach 200%

** Investment research firm sees CSL CSL being impacted by the tariffs as it processes some U.S. products in Australia, but doesn't expect earnings to take a material hit

** "Tariffs this high are unlikely to persist and CSL can adapt by onshoring manufacturing" - Morningstar

** Also anticipates Ansell ANN, Polynovo PNV, Nanosonics NAN, and Fisher & Paykel FPH to be impacted, if tariffs come into effect

** Says Telix TLX is enviably exempt from all potential tariffs on pharmaceuticals though shares remain overvalued

Morningstar Fair Value Estimates -